Antipruritic agent

Abstract: This invention provides an antipruritic comprising an opiate K receptor agonist as an effective component, and morphinian derivatives which are useful for the treatment of pruritus caused by various diseases.

Description: Technical Field The present invention relates to an opiate κ receptor agonist which is a morphinan-N-oxide derivative or its pharmacologically acceptable salt with an added acid represented by the general formula (III): wherein --- is a double bond, or a single bond; R 1 is alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, cycloalkenylalkyl having 5 to 7 carbon atoms, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; R 2 is hydrogen, hydroxy, nitro, alkanoyloxy having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, or alkyl having 1 to 5 carbon atoms; R 3 is hydrogen, hydroxy, alkanoyloxy having 1 to 5 carbon atoms, or alkoxy having 1 to 5 carbon atoms; R 4 is hydrogen, a straight or branched alkyl having 1 to 5 carbon atoms, or aryl having 6 to 12 carbon atoms; A is alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluormethyl, trifluormethoxy, and methylenedioxy; and the general formula (III) comprises (+), (-), and (±) isomers and an antipruritic comprising it which are useful for the treatment of pruritus caused by various diseases. Background Art Pruritus is an indication that is'peculiar to skin, and is observed in a variety of dermatoses with inflammation. Pruritus may be provoked by some internal diseases (malignant tumors, diabetes mellitus, hepatic diseases, renal failure, hemodialysis, gout, thyroid diseases, blood diseases, and iron deficiency), pregnancy, and vermination. In some cases, drugs and psychogenic causes may also provoke pruritus. Since pruritus is a subjective, it is difficult to evaluate it quantitatively and objectively. The mechanism that induces pruritus has not yet been completely clarified. Now, among the stimulants that are known to induce pruritus included are histamine, substance P, bradykinin, proteinases, prostaglandins, and opiate peptides. It is considered that pruritus is provoked by reaction of these pruritic stimulants to multistimuli-reacting nerve terminals existing at the border area between the epidermis and dermis (pruritic receptors), and by transfer of the resulting impulse to tractus spinothalamicus, thalamus, and cortex cerebri in that order ("The approach to the therapy for pruritus cutaneous", by Yoshiki Miyachi, p.22, 1996, Sentan Igakusya). Pruritus is a symptom in which patients experience significant discomfort, and in severe cases may cause significant disturbance of normal life. In the therapy for pruritus, primarily the treatment of dermatitis or an underlying disease that induces pruritus is necessary, and particularly in cases of dermatoses, simultaneous therapy for pruritus itself is necessary, because excoriation by a patient causes aggravation of symptoms. Excoriation is the most exacerbating factor of dermatitis, because excoriation injures the skin resulting in defect of barrier function, and erosion by physical or chemical stimuli and bacterial infection may easily occur. Also, since the epidermis becomes thin and fragile and nerves are sensitized, pruritus readily occurs. As a result, a vicious cycle of repeated excoriation begins. For example, although the period of excoriation resulting from pruritus during sleep is only 0.1% in healthy cases, the average period of excoriation by patients with severe atopic dermatitis amounts to 24%. If an average period of sleep is assumed to be 8 hours, the period of excoriation will reach about 2 hours. It is clear that the excoriation during sleep exacerbates atopic dermatitis and becomes a factor in the occurrence of atpoic exanthema ("NIKKEI MEDICAL", JULY 10, 1996, p13). Thus the therapy for pruritus itself may be a radical treatment, particularly in cases of dermatosis with significant pruritus. Examples of dermatoses generally subjected to therapy for such pruritus include atopic dermatitis, nervous dermatitis, contact dermatitis, seborrheic dermatitis, autosensitization dermatitis, caterpillar dermatitis, asteatosis, senile pruritus cutaneuos, insect sting, photosensitive dermatosis, urticaria, prurigo, herpes, impetigo, eczema, tinea, lichen, psoriasis, scabies, and acne vulgaris; and examples of visceral diseases complicated with pruritus and being particular problems include malignant tumors, diabetes mellitus, hepatic diseases, renal failure, hemodialysis, and pregnancy. Examples of drugs generally used for therapy for such pruritus include oral drugs, e.g. antihistamines, and antiallergic drugs; and dermatologic preparations, e.g. antihistamines, adrenocortical steroid dermatologic preparations, nonsteroidal anti-inflammatory drugs, camphor, menthol, phenol, salicylic acid, tar, crotamiton, capsaicin, and humectants (urea, Hirudoid, and petrolatum). However, oral drugs have some problems, e.g. a long lag time before presenting effects, and adverse events such as suppressive effects on the central nervous system (sleepiness and malaise) and impairment of the gastrointestinal system. Dermatologic preparations also have some problems, e.g. insufficient antipruritic effect, while topical steroids particularly cause some problems of adverse events such as decreased adrenocortical function caused by protracted administration and the rebound phenomenon. With regard to the relationship between opiates and pruritus, it has been clear that opiates have function not only as analgesics but also as chemical mediators of pruritus. It was first reported that endogenous opiate peptides such as β-endorphin and enkephalin induced pruritus (B. FjellerActa, Dermato-Venereol. , 61 (suppl. 97), 1-34,1981). It has been shown that morphine or opiate compounds induced pruritus as an adverse event when administered epidurally or intrathecally (J.H. Jaffe and W.R. Martin, Goodman and Gilman's Pharmacological Basis of Theraputics, Macmillan, New York, 1985). On the other hand, it has been also shown that pruritus which induced by morphine administered intrathecally was suppressed by naloxone, a morphine antagonist (J. Bernstein et al., J. Invest. Dermatol. , 78 , 82-83, 1982), and severe pruritus induced by increasing concentration of endogenous opiate peptides in cases of cholestasia with hepathopathy was suppressed by nalmefene (J. R. Thornton and M.S. Losowsky, Br. Med. J., 297 , 1501-1504, 1988). Generally, opiate agonists induce pruritus, whereas opiate antagonists are antipruritic. Recently, it has become evident that the serum concentration of β-endorphin in children with atopic dermatitis is significantly higher than that of healthy children. And it was reported that opiate antagonists were effective in pruritus induced by atopic dermatitis (S. Georgala et al., J. Dermatol. Sci., 8 , 125-128, 1994). Thus, it has been generally recognized that opiate agonists induce pruritus and opiate antagonists have a possibility as antipruritic. However, opiate antagonists do not have a practical use as an antipruritic at the present stage. An object of this invention is to provide an opiate κ receptor agonist which is a morphinan-N-oxide derivative or its pharmacologically acceptable salt with an added acid represented by the general formula (III): wherein --- is a double bond, or a single bond; R 1 is alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, cycloalkenylalkyl having 5 to 7 carbon atoms, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; R 2 is hydrogen, hydroxy, nitro, alkanoyloxy having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, or alkyl having 1 to 5 carbon atoms; R 3 is hydrogen, hydroxy, alkanoyloxy having 1 to 5 carbon atoms, or alkoxy having 1 to 5 carbon atoms; R 4 is hydrogen, a straight or branched alkyl having 1 to 5 carbon atoms, or aryl having 6 to 12 carbon atoms; A is alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluormethyl, trifluormethoxy, and methylenedioxy; and the general formula (III) comprises (+), (-), and (±) isomers and an antipruritic comprising it that solves the above problems and which has a significantly prompt and potent antipruritic activity. Disclosure of Invention The present invention provides an opiate κ receptor agonist which is a morphinan-N-oxide derivative or its pharmacologically acceptable salt with an added acid represented by the general formula (III): wherein --- is a double bond, or a single bond; R 1 is alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, cycloalkenylalkyl having 5 to 7 carbon atoms, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; R 2 is hydrogen, hydroxy, nitro, alkanoyloxy having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, or alkyl having 1 to 5 carbon atoms; R 3 is hydrogen, hydroxy, alkanoyloxy having 1 to 5 carbon atoms, or alkoxy having 1 to 5 carbon atoms; R 4 is hydrogen, a straight or branched alkyl having 1 to 5 carbon atoms, or aryl having 6 to 12 carbon atoms; A is alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluormethyl, trifluormethoxy, and methylenedioxy; and the general formula (III) comprises (+), (-), and (±) isomers and an antipruritic comprising it as an effective component. Best Mode for Carrying Out the Invention It is known that there are µ, δ, and κ opiate receptors, and endogenous opiate peptides each selectively stimulating corresponding receptors have been discovered. In other words, β-endorphin and enkephalin are identified as µ, and δ receptor agonists, respectively, and dynorphin has been identified as an endogenous opiate peptide acting as a specific κ receptor agonist. The effect of action of κ receptor agonists including dynorphin on pruritus has not been clear, this invention, however, makes it clear for the first time. Although the κ receptor agonists of this invention may not have any chemical structural specificity regarding agonistic action on opiate κ receptors, the agonists preferably have higher specificity for κ receptors than µ, and δ receptors. More particularly, morphinan derivatives or their pharmacologically acceptable salts with an added acid having an opiate κ receptor agonistic activity are represented by the general formula (III): wherein --- is a double bond, or a single bond; R 1 is alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, cycloalkenylalkyl having 5 to 7 carbon atoms, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; R 2 is hydrogen, hydroxy, nitro, alkanoyloxy having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, or alkyl having 1 to 5 carbon atoms; R 3 is hydrogen, hydroxy, alkanoyloxy having 1 to 5 carbon atoms, or alkoxy having 1 to 5 carbon atoms; R 4 is hydrogen, a straight or branched alkyl having 1 to 5 carbon atoms, or aryl having 6 to 12 carbon atoms; A is alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluoromethyl, trifluoromethoxy and methylenedioxy; and the general formula (III) comprises (+), (-), and (±) isomers. Examples of dermatoses complicated with pruritus as the subject for treatment include atopic dermatitis, nervous dermatitis, contact dermatitis, seborrheic dermatitis, autosensitization dermatitis, caterpillar dermatitis, asteatosis, senile pruritus cutaneous, insect sting, photosensitive dermatosis, urticaria, prurigo, herpes, impetigo, eczema, tinea, lichen, psoriasis, scabies, and acne vulgaris. Typical examples of visceral diseases complicated with pruritus as the subject include malignant tumors, diabetes mellitus, hepatic diseases, renal failure, hemodialysis, and pregnancy. In addition, it can be applied to pruritus being a complication of ophthalmic diseases or otorhinolaryngologic diseases. The compounds represented by general formula (III) are new morphinan N-oxide derivatives at 17 position, and opiate κ receptor agnonists. In that formula, R 1 is preferably alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, Cycloalkenylalkyl having 5 to 7 carbons, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; and particularly methyl, ethyl, propyl, butyl, isobutyl, cyclopropylmethyl, cyclobutylmethyl, cyclopenthylmethyl, cyclopentenylmethyl, cyclohexenylmethyl, benzyl, phenetyl, trans-2-butenyl, 2-methyl-2-butenyl, or allyl is preferred. More preferred is methyl, ethyl, propyl, butyl, isobutyl, cyclopropylmethyl, benzyl, phenetyl or allyl. R 2 is preferably hydrogen, hydroxy, nitro, acetoxy, methoxy, methyl, ethyl or propyl; and particularly hydrogen, hydroxy, acetoxy or methoxy is preferred. R 3 is preferably hydrogen, hydroxy, acetoxy or methoxy. R 4 is preferably hydrogen, straight or branched alkyl having 1 to 5 carbon atoms or phenyl; and particularly straight or branched alkyl having 1 to 5 carbon atoms is preferred. Of them, methyl, ethyl, propyl, isopropyl, butyl or isobutyl is more preferred. "A" is preferably alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and of them -CH=CH- or -C=C- is more preferred. R 5 is preferably an organic group having any one of the following basic skeletons: (where the organic group may have its component substituted by at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluoromethyl, trifluoromethoxy and methylenedioxy); and particularly phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4--difluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromehylphenyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-furanyl, 3-furanyl, cyclopentyl, or cyclohexyl is preferred, but of course it should not be limited to them. Concrete examples of the compounds as represented by general formula (III) are shown in Table 1. The compounds represented by general formula (III) comprise (+), (-) and (±) isomers. The compounds of this invention represented by general formula (III) can be obtained, to put it specifically, by the following method. Generally, as shown by Chart 1, obtainment of the compounds can be achieved by the steps of oxidizing tertiary amine at 17 position of the starting material represented by general formula (IX) (where R 1 , R 2 , R 3 , R 4 , R 5 and A represent the same as defined in general formula (III)) with an organic peroxide such as m-chloroperbenzoic acid, performic acid, peracetic acid, perbenzoic acid, trifluoro peracetate, permaleic acid and perphthalic acid, but the oxidants should not be limited to them. The starting material including tertiary amine at 17 position represented by general formula (VIII) can be produced by the method disclosed in Japanese Patent No. 2525552. There are many oxidizing agents that can be used for converting the starting material as represented by general formula (IX) into a tertiary amine N-oxide (III). m-chloroperbenzoic acid is convenient because generally it reacts comparatively rapidly to produce an N-oxide. However, other organic peroxides such as performic acid, peracetic acid, perbenzoic acid, trifluoro peracetate, permaleic acid and perphthalic acid may be used. Or alternatively, the oxidizing agent may be generated in the reaction system: a tertiary amine is dissolved in, for example, formic acid, acetic acid or trifluoro acetate, and aqueous hydrogen peroxide with a concentration of 3-50%, or more preferably with a concentration of 30-50% is added thereto. As a solvent, the halogen solvent such as methylene chloride, chloroform or 1,2-dichloroethane, the aromatic solvent such as benzene or toluene, the ether solvent such as diethylether or tetrahydroflan, the alcohol solvent such as methanol, ethanol, propanol or tertiary buthanol may be used as the reaction medium. Or alternatively, when the oxidizing agent is generated in the reaction system, the corresponding acid may be used as the reaction medium as appropriate. Instead of the organic peroxides described above, peroxides such as hydrogen peroxide may be used. Aqueous hydrogen peroxide alone may be used at a concentration of 3-50%, or it may be used in conjunction with a solvent like the one described above. Other usable oxidizing agents include ozone, tertiary butylhydroperoxide and cumene hydroperoxide. Generally, the oxidizing agent may be used at 0°C to the boiling point of solvent, or more specifically at room temperature to the boiling point of solvent, for several minutes to three days, or more specifically for one to 24 hours. The aforementioned oxidizing agent may be added by one equivalent with respect to one equivalent of tertiary amine, or it may be further added, for example, 10-100% excess or more excess to amine. When excess peroxide (which is easily detected by the use of iodine/starch paper) is present on completion of the reaction, addition of an inorganic reducing agent such as sodium bisulfite or sodium sulfite, a metal catalyst such as 5% platinum or palladium bound to carbon or alumina, or an organic reducing agent such as dimethylsulfide will ensure a proper treatment. Other oxidizing agents to be used for the production of tertiary amine oxide include ozone in a solvent (for example, in chloroform, methylene chloride, fluorene or methanol), ozone adsorbed onto silica gel, hydroperoxide such as tertiary butylhydroperoxide, as desired, in the presence of a catalyst such as a vanadium compound. When cost is important, for example, when the product is manufactured in an industrial scale, the preferable reaction agent is 30-50% aqueous hydrogen peroxide dissolved in tertiary buthanol. For example, when several kg of morphinan derivative (general formula (IX)) is allowed to react with 50% aqueous hydrogen peroxide dissolved in boiling tertiary buthanol for two and a half hours, it can be oxidized into a morphinan-N-oxide derivative (general formula (III)). In the production of said κ receptor agonists, the pharmacologically acceptable, acid-supplementing salt to be added to the compounds represented by formulae (III), may preferably include inorganic salts such as hydrochloric acid salts, sulfates, nitrates, hydrobromic acid salts, hydriodic acid salts, phosphates, etc.; organic carbonate such as acetates, lactates, succinates, oxalates, glutarates, malates, tartrates, fumarates, mandelates, maleates, benzoates, phthalates, etc.; and organic sulfonates such as methane sulfonates, ethane sulfonates, benzene sulfonates, p-toluene sulfonates, camphor sulfonates, etc. Of them, hydrochloric acid salts, hydrobromic acid salts, phosphates, tartrates, methane sulfonates and the like are preferred, but of course what is preferable is not limited to above. These κ receptor agonists may be refined sufficiently pure to be used as a medicinal preparation, and, after having passed the necessary safety test, as the neat state or as a composition to be combined with a publicly known or pharmacologically accepted acid, vehicle, excipient or the like, can be administered orally or parenterally. The oral preparation may occur as tablets and capsules, but, when used for the treatment of skin diseases, preferably may occur as topical preparations. Preparation of the topical preparations may comprise the steps of combining a fat (preferably, plant oil, animal oil, wax, fatty acid, fatty alcohol, mineral oil, turpentine oil, vaseline, etc.), a solvent (preferably, water, ethanol, glycerin, propylene glycol, isopropyl alcohol, ether, etc.), a preserving agent (preferably, paraoxybenzoic acid ester, benzoic acid, salicylic acid, sorbic acid, benzalkonium, benzethonium, propyleneglycol, chlorobuthanol, benzyl alcohol, ethanol, etc.), a stabilizer (preferably, tocopherol, butylhydroxyanisol, dibutylhydroxytoluene, sulfites, edetic acid disodium, etc.), an anionic surfactant (preferably, potassium soap, medical soap, zinc undecylenate, calcium stearate, magnesium stearate, aluminum monostearate, calcium linolate, sodium laurylsulfate, etc.), a non-ionic surfactant (preferably, glyceryl monostearate, sorbitan fatty acid partial esters, sugar fatty acid ester, stearic acid polyoxyl 40, macrogolic acids, lauromacrogol, polyoxyethylene160polyoxypropylene30glycol, polyoxyethylene hardened castor oil, polyoxyethylene sorbitan fatty acid partial esters, etc.), a cationic surfactant (preferably, benzalkonium chloride, benzethonium chloride, cetyl piridinium chloride, etc.), powders (preferably, zinc oxide, zinc powder in starch, kaolin, bismuth hyponitrite, titanium oxide, titanium dioxide, sulfur, anhydrous silicic acid, tarc, etc.), a preserving agent (preferably, paraoxybenzoic acid ester, sorbic acid, p-chloro-m-xylenol, Irgasan, hexachlorophene, etc.), an emulsifier (preferably, arabic gum powder, tragacanth powder, bentonite, carboxymethylcellulose sodium, methylcellulose, etc.), and a moisturizer (preferably, glycerin, propylene glycol, polyethylene glycol, 1,3-butylene glycol, sorbitol, polypyrrolidone carboxylic acid sodium, sodium lactate, sodium hyaluronate, chitin derivatives, urea, amino acids, sugar amino acid, etc.) to form a base, and of preparing it not only as an ointment, cream, emollient, lotion, patch, etc., but as a liquid preparation for topical use. Further, the preparation may be made as a solution for topical ophthalmic use. The content of κ receptor agonist in a medicinal composition is not limited to any specific range, but the composition, to be used orally, should be prepared so that one ingestion may contain usually 0.1µg-1000mg, and, to be used topically, should be prepared so that one application may give a dose of usually 0.001ng/m 2 - 10mg/m 2 . [Examples] This invention will be described below in concrete terms by means of Examples. EXAMPLE 1 17-cyclopropylmethyl-4,5α-epoxy-3, 14β-dihydroxy-6β-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan-N-oxide 1 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan 600mg (1.26mmol) was dissolved in tetrahydrofuran 30ml; and to this solution was added dropwise at 0°C for 15 minutes a solution which was obtained after m-chlorobenzoic acid 348mg had been added to tetrahydrofuran 8ml. On completion of the dropwise addition, the reaction solution was stirred at room temperature for about one hour and half, to which was added a mixture of chloroform/methanol (4:1), to dissolve precipitated solid in the reaction solution. The solution was concentrated; the resulting residue was purified by column chromatography [filled with alkaline alumina 20g and chloroform/methanol (10:0 to 10:1)]; and the yield was recrystallized with ethyl acetate-methanol, to give the compound 473mg (yield being 76%) in the title. mp: 238-239.8°C (decomposition) NMR(600MHz, CDCl 3 ) δ 0.38(1H, m), 0.45(1H, m), 0.76(2H, m), 1.34(1H, m), 1.46(1H, m), 1. 61(2H, m), 1.76(1H, m), 2.25(0.2H, m), 2.42(0.8H, m), 2.90-3.03(1H, m), 3.05(2.4H, s), 3.06-3.22(4.6H, m), 3.41(2H, m), 3.72(0.8H, m), 3.79(1H, m), 4.58(0.2H, m), 4.67(0.8H, d, J=7.0Hz), 4.75(0.2H, d, J=7.0Hz), 6.3 5(0.8H, d, J=15.3Hz), 6.59(0.2H, d, J=8.2Hz), 6.61(0.2H, d, J=15.3Hz), 6.64(0.8H, d, J=8.2Hz), 6.68(0.8H, s), 6.83(0.2H, d, J=8.2Hz), 6.91(0.8 H, d, J=8.2Hz), 7.32(0.8H, d, J=15.3Hz), 7.33(1H, s), 7.38(0.8H, s), 7. 43(0.2H, s), 7.55(0.2H, d, J=15.3Hz), 7.62(0.2H, s), 9.49(1H, br s),12. 12(1H, br s). IR(KBr) ν 3420, 1653, 1605, 1504, 1408, 1321, 1160, 872 cm -1 . Mass(FAB) m/z 493 (M+H) + . Elementary analysis C 28 H 32 N 2 O 6 .0.2AcOEt: calculated values C, 67.80; H, 6.64; N, 5.49 measured values C, 67.80; H, 6.67; N, 5.65 EXAMPLE 2 17-cyclopropylmethyl-4,5α-epoxy-3, 14β-dihydroxy-6β-(N-methyl-3-methoxycinnamamido) morphinan-N-oxide 2 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-(N-methyl-3-methoxycinnamamido) morphinan 405mg was dissolved in tetrahydrofuran 20ml; and to this solution was added dropwise at 0°C for ten minutes a solution which was obtained after m-chlorobenzoic acid 225mg had been added to tetrahydrofuran 5ml for dissolution. On completion of the dropwise addition, the reaction solution was stirred at room temperature for about 40 minutes; the reaction solution was concentrated; the residue was submitted to column chromatography based on the use of alkaline alumina 20g; and the yield was recrystallized with ethyl acetatelmethanol, to give the compound 329mg (yield being 79%) in the title. mp: 234-236.8°C (decomposition) NMR(600MHz, CDCl 3 ) δ 0.35(1H, m), 0.42(1H, m), 0.74(2H, m), 1.34(1H, m), 1.45(1H, m), 1. 61 (2H, m), 1.72(1H, m), 1.81(2H, m), 2.24(0.3H, m), 2.41(0.7H, m), 2.86 -2.97(1H, m), 2.97-3.14(2H, m), 3.06(2.1H, s), 3.15(0.9H, s), 3.32-3.44 (2H, m), 3.70-3.80(1.7H, m), 3.83(3H, s), 4.62(0.3H, m), 4.70(1H, d, J= 7.9Hz), 6.57-6.68(0.7H, m), 6.58(0.3H, d, J=7.9Hz), 6.62(0.7H, d, J=8.2 Hz), 6.77(0.7H, dd, J=8.2 and 2.1Hz), 6.82(0.3H, d, J=8.2Hz), 6.84(0.7H, d, J=8.2Hz), 6.86(1H, d, J=15.6Hz), 6.91(0.3H, dd, J=8.2 and 2.1Hz), 6. 94(0.7H, d, J=7.3Hz), 7.03(0.3H, s), 7.11(0.3H, d, J=7.6Hz), 7.15(0.7H, t, J=7.9Hz), 7.29(0.3H, t, J=7.9Hz), 7.40(0.7H, d, J=15.6Hz), 7.62(0.3H , d, J=15.3Hz), 9.00(1H, br s), 12.15(1H, br s). IR(KBr) ν 3420, 1647, 1593, 1495, 1408, 1321, 1160, 917, 855 cm -1 . Mass(FAB) m/z 533 (M+H) + . Elementary analysis C 31 H 36 N 2 O 6 .0.3H 2 O: calculated values C, 69.20; H, 6.86; N, 5.21 measured values C, 68.11; H, 6.87; N, 5.21 EXAMPLE 3 17-cyclopropylmethyl-4,5α-epoxy-3, 14β-dihydroxy-6β-[N-methyl-3-(4-trifluoromethylphenyl) propyolamido] morphinan-N-oxide 3 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[N-methyl-3-(4-trifluoromethylphenyl) propyolamido] morphinan 413mg was dissolved in tetrahydrofuran 20ml; and to this solution was added dropwise at 0°C for 15 minutes a solution which was obtained after m-chlorobenzoic acid 205mg had been added to tetrahydrofuran 5ml for dissolution. On completion of the dropwise addition, the reaction solution was stirred at room temperature for about one hour; the reaction solution was concentrated; the residue was submitted to column chromatography based on the use of alkaline alumina 20g; and the yield was recrystallized with ethyl acetate/methanol, filtered and dried in a vacuum, to give the compound 304mg (yield being 74%) in the title. mp: 205-208°C (decomposition) NMR(600MHz, CDCl 3 ) δ 0.37(1H, m), 0.44(1H, m), 0.76(2H, m), 1.35(0.2H, m), 1.47(1.8H, m), 1.62(2H, m), 1.75(0.2H, m), 1.82(0.8H, m), 2.27(0.2H, m), 2.42(0.8H, m), 2.92(0.8H, m), 2.99(0.2H, m), 3.02-3.12(2H, m), 3.05(2.4H, s), 3. 12-3.22(2H, m), 3.31(0.6H, s), 3.40(2H, m), 3.79(1H, m), 4.22(0.8H, m), 4.50(0.2H, m), 4.74(0.8H, d, J=7.9Hz), 4.76(0.2H, d, J=7.9Hz), 6.00-7.2 0(1H, br s), 6.56-6.64(1.8H, m), 6.83(0.2H, d, J=7.9Hz), 7.40(1.6H, d, J=7.9Hz), 7.55(1.6H, d, J=8.2Hz), 7.64(0.4H, d, J=8.5Hz), 7.66(0.4H, d, J= 8.5Hz), 12.22(1H, br s). IR(KBr) ν 3420, 2224, 1615, 1506, 1408, 1325, 1170, 1129, 1067 cm -1 . M ass (FAB) m/z 569 (M+H) + . Elementary analysis C 31 H 31 N 2 O 5 F 3 .0.2C 6 H 12 .0.1AcOEt: calculated values C, 65.89; H, 5.80; N, 4.71; F, 9.59 measured values C, 65.71; H, 5.86; N, 4.73; F, 9.52 EXAMPLE 4 17-cyclopropylmethyl-4,5α-epoxy-3, 14β-dihydroxy-6β-[N-methyl-3-(3-methylphenyl) propyolamido] morphinan-N-oxide 4 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[N-methyl-3-(3-methylphenyl) propyolamido] morphinan 408mg was dissolved in tetrahydrofuran 20ml; and to this solution was added dropwise at 0°C for 15 minutes a solution which was obtained after m-chlorobenzoic acid 244mg had been added to tetrahydrofuran 5ml for dissolution. On completion of the dropwise addition, the reaction solution was stirred at room temperature for about one hour; the reaction solution was concentrated; the residue was submitted to column chromatography based on the use of alkaline alumina 20g; and the yield was recrystallized with ethyl acetate/methanol, filtered and dried in a vacuum, to give the compound 269mg (yield being 64%) in the title. mp: 192.0-202.0°C (decomposition) NMR(600MHz, CDCl 3 ) δ 0.37(1H, m), 0.44(1H, m), 0.75(2H, m), 1.35(0.3H, m), 1.40-1.53(1. 7H, m), 1.54-1.66(2H, m), 1.68-1.85(2H, m), 2.20-2.32(0.3H, m), 2.31(2. 1H, s), 2.36(0.9H, s), 2.36-2.45(0.7H, m), 2.86-3.00(1H, m), 3.00-3.22 (3H, m), 3.03(2.1H, s), 3.31(0.9H, s), 3.34-3.46(2H, m), 3.77(0.3H, m), 3.79(0.7H, m), 4.30(0.7H, m), 4.50(0.3H, m), 4.73(0.7H, d, J=8.2H z), 4. 75(0.3H, d, J=8.5Hz), 6.20-7.20(1H, br s), 6.59(0.3H, d, J=8.2Hz), 6.60 (0.7H, d, J=8.2Hz), 6.63(0.7H, d, J=8.2Hz), 6.82(0.3H, d, J=8.2Hz), 7.04(0.7H, s), 7.08(0.7H, d, J=6.1Hz), 7.13-7.20(1.4H, m), 7.23(0.3H, d, J =7.6Hz), 7.26(0.3H, t, J=7.3Hz), 7.35(0.3H, d, J=7.6Hz), 7.37(0.3H, s), 12.22(1H, br s). IR(KBr) ν 3410, 2218, 1622, 1489, 1439, 1408, 1377, 1321, 1125, 1033, 915, 690 cm -1 . Mass(FAB) m/z 515 (M+H) + . Elementary analysis C 31 H 34 N 2 O 5 .0.5H 2 O: calculated values C, 71.11; H, 6.74; N, 5.35 measured values C, 71.16; H, 6.73; N, 5.37 EXAMPLE 5 Assay of opioid activity by Guinea pig ileum assay. Male Hartley guinea pigs were used. The guinea pig was killed with a blow, and the ileum excised; the lumen of ileum was washed with a nutritious fluid; and only a piece of longitudinal muscle was stripped. This longitudinal muscle strip was suspended in a Magnus tube filled with Krebes-Henseleit solution (NaCl 135mM; KCl 4.8mM; CaCl 2 3.4mM; KH 2 PO 4 1.2mM; NaHCO 3 8.3mM; MgSO 4 , 2.5mM; and glucose 11mM) kept at 37°C,and gassed with a mixture of 5% carbon dioxide and 95% oxygen. Electrical stimulation was delivered at a rate of 0.1Hz with 0.5ms pulses through ring-shaped platinum electrodes placed at upper and lower levels in a Magnus tube. Tissue contractions were recorded via an isometric transducer on a polygraph. The test drug was cumulatively added until it inhibited over 50% the contraction of specimen evoked by the electrical stimulation, in the presence or absence of naloxone as a µ antagonist, or nor-BNI as a κ antagonist, and IC50s were calculated for respective experimental conditions. From the difference in drug efficacy in the presence and absence of the antagonist, Ke values were calculated on the basis of following equations. Ke = [Concentration of antagonist added]/(IC 50 ratio - 1) IC 50 ratio = IC 50 in the presence of antagonist/IC 50 in the absence of antagonist Compounds 1, 2, 3, 4, were used as the test drug. When the ratio of Ke(µ) against Ke(κ) is calculated from the data shown in Table 2, Ke(µ)/Ke(κ) value ranges from 182 to ∞, which indicates that the compounds of this invention are agonists selectively acting on a κ receptor. Opiod activity of Compounds evaluated by guinea pig ileum assay IC50(nM) Ke (nM) Naloxone (100nM) nor-BNI (5nM) 1 1.06 - 0.02 2 4.09 28.7 0.09 3 1.55 29.5 0.19 4 11.3 75.1 0.89 EXAMPLE 6 Assay of opioid activity by mouse vas deferens assay Male ddY mice were used for the experiment. The vas deferens specimen removed from the animal was suspended in a Magnus tube filled with Krebes-Henseleit solution (NaCl 120.7nM; KCl 5.9mM; CaCl 2 2.5mM; NaH 2 PO 4 1.2mM; NaHCO 3 15.5mM; and glucose 11.5mM) kept at 37°C, and gassed with a mixture of 5% carbon dioxide and 95% oxygen. Electrical stimulation was delivered at a rate of 0.1Hz with 1.0ms pulses through ring-shaped platinum electrodes placed at upper and lower levels in a Magnus tube. Tissue contractions were recorded via an isometric transducer on a polygraph. The test drug was cumulatively added until it inhibited over 50% the contraction of specimen evoked by the electrical stimulation, in the presence or absence of naloxone as a µ antagonist, or nor-BNI as a κ antagonist, and IC 50 s were calculated for respective experimental conditions. From the difference in drug efficacy in the presence and absence of the antagonist, Ke values were calculated on the basis of following equations. Ke = [Concentration of antagonist added]/(IC 50 ratio - 1) IC 50 ratio = IC 50 in the presence of antagonist/IC 50 in the absence of antagonist Compounds 1, 2, 3, 4 were used as the test drug. When the ratio of Ke(µ) against Ke(κ), and Ke(δ) · against Ke(κ) values are calculated using the value listed on Table 3, Ke(µ)/Ke(κ) value ranges from 18 to ∞, and Ke(δ)/Ke(κ) does from 15 to ∞ respectively, which indicates that the compounds of this invention are agonists selectively acting on a κ receptor. Opioid activity of Compounds by rat vas deferens assay IC50(nM) Ke (nM) Naloxone (30nM) NTI (10nM) nor-BNI (10nM) 1 2.14 30.48 - 0.040 2 1.80 50 11 0.67 3 0.59 5.9 5.0 0.33 4 4.6 - 20 0.26 EXAMPLE 7 Male ddY mice were purchased from Japan SLC when they were 4 weeks old, and used in the experiments when they became 5 weeks old after acclimation. The day before experiment, the mouse had hair on the rostral back skin clipped with a hair clipper. Each of test drug was dissolved in 10% DMSO. Either of the test drug or solvent was administered subcutaneously into rostral back of the mouse, and 30 minutes later Compound 48/80 dissolved in saline was administered intradermally into the hair-clipped skin at a dose of about 50µl (100µg/site). Immediately thereafter, the mouse was put into a cage for observation (10 x 7 x 16cm), and the subsequent behavior of the mouse was recorded with a video camera under unmanned conditions. The video tape was replayed, and the number of the scratching of the Compound 48/80-treated site or its vicinity by hind paws was counted. Each experimental group comprised 8 to 10 animals. Inhibition percent of scratching by the test compound was calculated by averaging the inhibition of scratching behavior(%) of each mice, which is obtained on the basis of the following equation. The degree of inhibition was regarded as correlated with antipruritic potential of the test compound. Inhibition of scratching behavior (%) = [1-(A - C/B - C)] x 100 A = Average scratching count of the group which received a test drug B = Average scratching count of the group which received solvent instead of a test drug C = Average scratching count of the group which received solvent instead of the pruritic agent The test compounds used included 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan-N-oxide 1 ; 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-3-(4-trifluoromethylphenyl) propyolamido] morphinan-N-oxide 3 ; 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-3-(3-methylphenyl) propyolamido] morphinan-N-oxide 4 ; The results are summarized in Table 4. The compounds used for the test exhibited an antipruritic activity at the dose used. Antipruritic activities Test preparation Dose (mg/kg) Inhibition (%) Compound 1 0.0057 64 Compound 3 0.016 55 Compound 4 0.005 45 Industrial Applicability An antipruritic of this invention comprises an opiate κ receptor agonist which is a morphinan-N-oxide derivative or its pharmacologically acceptable salt with an added acid represented by the general formula (III): wherein --- is a double bond, or a single bond; R 1 is alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, cycloalkenylalkyl having 5 to 7 carbon atoms, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; R 2 is hydrogen, hydroxy, nitro, alkanoyloxy having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, or alkyl having 1 to 5 carbon atoms; R 3 is hydrogen, hydroxy, alkanoyloxy having 1 to 5 carbon atoms, or alkoxy having 1 to 5 carbon atoms; R 4 is hydrogen, a straight or branched alkyl having 1 to 5 carbon atoms, or aryl having 6 to 12 carbon atoms; A is alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluormethyl, trifluormethoxy, and methylenedioxy; and the general formula (III) comprises (+), (-), and (±) isomers as an effective component, and is useful for dermatoses with pruritus such as atopic dermatitis, nervous dermatitis, contact dermatitis, seborrheic dermatitis, autosensitization dermatitis, caterpillar dermatitis, asteatosis, senile pruritus cutaneous, insect sting, photosensitive dermatosis, urticaria, prurigo, herpes, impetigo, eczema, tinea, lichen, psoriasis, scabies, and acne vulgaris; visceral diseases complicated with pruritus such as malignant tumors, diabetes mellitus, hepatic diseases, renal failure, hemodialysis, and pregnancy.

Claims: A morphinan-N-oxide derivative or its pharmacologically acceptable salt with an added acid represented by the general formula (III): wherein --- is a double bond, or a single bond; R 1 is alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7, carbon atoms, cycloalkenylalkyl having 5 to 7 carbon atoms, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; R 2 is hydrogen, hydroxy, nitro, alkanoyloxy having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, or alkyl having 1 to 5 carbon atoms; R 3 is hydrogen, hydroxy, alkanoyloxy having 1 to 5 carbon atoms, or alkoxy having 1 to 5 carbon atoms; R 4 is hydrogen, a straight or branched alkyl having 1 to 5 carbon atoms, or aryl having 6 to 12 carbon atoms; A is alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluormethyl, trifluormethoxy, and methylenedioxy; and the general formula (III) comprises (+), (-), and (±) isomers. A derivative according to claim 1, wherein the morphinan-N-oxide derivative is represented by the general formula (III), wherein R 1 is methyl, ethyl, propyl, butyl, isobutyl, cyclopropylmethyl, allyl, benzyl, or phenetyl; R 2 and R 3 are hydrogen, hydroxy, acetoxy, or methoxy independently; R 4 is hydrogen or a straight or branched alkyl having 1 to 5 carbon atoms; and A is -CH=CH- or -C≡C-. A derivative according to claim 2, wherein the morphinan-N-oxide derivative is represented by the general formula (III), wherein R 4 is methyl, ethyl, propyl, isopropyl, butyl, or isobutyl. A derivative according to claim 2, wherein the morphinan-N-oxide derivative is represented by the general formula (III), wherein R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluoromethyl, trifluoromethoxy and methylenedioxy. A derivative according to claim 4, wherein the morphinan-N-oxide derivative is represented by the general formula (III), wherein R 4 is methyl, ethyl, propyl, isopropyl, butyl, or isobutyl. A derivative according to any one of claims 1 to 5 for the use as an antipruritic. A derivative according to claim 6, wherein pruritus is a complication of dermatosis or visceral disease. A drug comprising a morphinan-N-oxide derivative or its pharmacologically acceptable salt with an added acid according to any one of claims 1 to 5. A method for producing a compound represented by the general formula (III) characterized in that a tertiary amine represented by the general formula (IX) is oxidized with an oxidizing reagent: wherein in the above general formulas (IX) and (III), --- is a double bond, or a single bond; R 1 is alkyl having 1 to 5 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, cycloalkenylalkyl having 5 to 7 carbon atoms, aralkyl having 7 to 13 carbon atoms, alkenyl having 4 to 7 carbon atoms, or allyl; R 2 is hydrogen, hydroxy, nitro, alkanoyloxy having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms or alkyl having 1 to 5 carbon atoms; R 3 is hydrogen, hydroxy, alkanoyloxy having 1 to 5 carbon atoms, or alkoxy having 1 to 5 carbon atoms; R 4 is hydrogen, a straight or branched alkyl having 1 to 5 carbon atoms, or aryl having 6 to 12 carbon atoms; A is alkylene having 1 to 6 carbon atoms, -CH=CH-, or -C≡C-; and R 5 is an organic group having any one of the following fundamental structures: wherein the organic group may have at least one substituent selected from the group consisting of alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, alkanoyloxy having 1 to 5 carbon atoms, hydroxy, fluorine, chlorine, bromine, iodine, nitro, cyano, isothiocyanato, trifluoromethyl, trifluoromethoxy, and methylenedioxy. A method according to claim 9, wherein the oxidizing reagent is a peroxide selected from the group consisting of organic carboxylic acids, hydrogen peroxide, tertiary butyl hydroperoxide, cumene hydroperoxide, and ozone.

Inventors: ENDOH TAKASHI, KAMEI JUNZO, KAWAMURA KUNIAKI, NAGASE HIROSHI, TANAKA TOSHIAKI, UTSUMI JUN, ENDOH, TAKASHI, KAMEI, JUNZO, KAWAMURA, KUNIAKI, NAGASE, HIROSHI, TANAKA, TOSHIAKI, UTSUMI,JUN
Applicants: TORAY INDUSTRIES, TORAY INDUSTRIES, INC.
Application year: 1997
Main classification: A61K31
IPC codes: A61K31, A61P17, C07D489